FY2025 EPS Estimates for Omnicell Cut by Zacks Research

Omnicell, Inc. (NASDAQ:OMCL) – Zacks Research reduced their FY2025 earnings estimates for Omnicell in a research note issued on Wednesday, January 7th. Zacks Research analyst Team now expects that the company will earn $0.92 per share for the year, down from their previous forecast of $1.01. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2025 earnings at $0.25 EPS, Q1 2026 earnings at $0.09 EPS, Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at $0.34 EPS, FY2026 earnings at $0.93 EPS, Q1 2027 earnings at $0.18 EPS, Q2 2027 earnings at $0.27 EPS, Q3 2027 earnings at $0.27 EPS, Q4 2027 earnings at $0.28 EPS and FY2027 earnings at $1.00 EPS.

OMCL has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a report on Wednesday, January 7th. Wells Fargo & Company raised their price objective on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Finally, Benchmark lifted their target price on Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $47.83.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $51.19 on Monday. The firm has a 50 day moving average of $41.42 and a 200-day moving average of $34.48. Omnicell has a 12 month low of $22.66 and a 12 month high of $51.30. The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.30 billion, a PE ratio of 119.05, a PEG ratio of 5.40 and a beta of 0.77.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its position in shares of Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after purchasing an additional 5,311 shares in the last quarter. Empowered Funds LLC lifted its stake in Omnicell by 14.3% in the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after buying an additional 1,243 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock worth $4,337,000 after buying an additional 4,866 shares in the last quarter. Jane Street Group LLC grew its position in shares of Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after buying an additional 109,382 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in shares of Omnicell during the 1st quarter worth approximately $4,394,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the transaction, the executive vice president owned 91,674 shares in the company, valued at $4,574,532.60. This trade represents a 6.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.52% of the stock is owned by corporate insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.